United TherapeuticsUTHR -0.98%88 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $387.00 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 516 Drug Manufacturers companies, United Therapeutics ranks worse than 193798.26% on this metric.
United Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for United Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
UTHR's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.24 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
United Therapeutics (NAS:UTHR) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
United Therapeutics 5-Year Yield-on-Cost % Related Terms
UTHR vs VTRS, NBIX, ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's 5-Year Yield-on-Cost % falls into.
United Therapeutics 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
United Therapeutics (UTHR) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on United Therapeutics and its competitors. According to the industry distribution chart, United Therapeutics ranks #999999 out of 516 companies in the Drug Manufacturers industry.
Is United Therapeutics' 5-Year Yield-on-Cost % too high?
United Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, United Therapeutics ranks #999999 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' 5-Year Yield-on-Cost % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #999999 out of 516 companies for 5-Year Yield-on-Cost %. This places United Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.24, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.00, compared to a current price of $547.06 — trading 41.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For United Therapeutics (UTHR), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $547.06 is trading 41.4% above its estimated GF Value™ of $387.00.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
5-Year Yield-on-Cost %: 0.00
GF Value™: $387.00 vs. price of $547.06 (41.4% above fair value)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 